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Sorting nexin 9 differentiates ligand-activated 
Smad3 from Smad2 for nuclear import and 
transforming growth factor β signaling
ABSTRACT Transforming growth factor β (TGFβ) is a pleiotropic protein secreted from es-
sentially all cell types and primary tissues. While TGFβ’s actions reflect the activity of a num-
ber of signaling networks, the primary mediator of TGFβ responses are the Smad proteins. 
Following receptor activation, these cytoplasmic proteins form hetero-oligomeric complexes 
that translocate to the nucleus and affect gene transcription. Here, through biological, bio-
chemical, and immunofluorescence approaches, sorting nexin 9 (SNX9) is identified as being 
required for Smad3-dependent responses. SNX9 interacts with phosphorylated (p) Smad3 
independent of Smad2 or Smad4 and promotes more rapid nuclear delivery than that ob-
served independent of ligand. Although SNX9 does not bind nucleoporins Nup153 or 
Nup214 or some β importins (Imp7 or Impβ), it mediates the association of pSmad3 with 
Imp8 and the nuclear membrane. This facilitates nuclear translocation of pSmad3 but not 
SNX9.
INTRODUCTION
Transforming growth factor β (TGFβ) regulates a variety of cellular 
processes, including matrix deposition, mitosis, development, 
differentiation, and apoptosis (Roberts and Wakefield, 2003; 
Elliott and Blobe, 2005). The primary intracellular mediators of TGFβ 
action are the Smad proteins, although non-Smad pathways have 
been reported, often in a cell type–specific context (Rahimi and 
Leof, 2007; Ross and Hill, 2008). Three general categories of Smads 
have been identified: receptor-regulated Smads (R-Smads; Smad2 
and Smad3 for TGFβ or Activin and Smad1, Smad5, and Smad8 
for bone morphogenetic proteins); common-mediator Smad 
(Co-Smad; Smad4); and inhibitory Smads (I-Smads; Smad6 and 
Smad7). The R- and Co-Smad proteins shuttle continuously be-
tween the nucleus and cytoplasm in unstimulated cells and in the 
presence of TGFβ (Inman et al., 2002; Xu et al., 2002; Schmierer and 
Hill, 2005).
The import and nuclear translocation of cargo generally requires 
association with specific transport receptors (karyopherins) and in-
teractions with various nuclear pore complex proteins (nucleoporins) 
(Chook and Suel, 2011; Marfori et al., 2011). Although a great deal 
of information concerning Smad nuclear import has been gener-
ated, and there is evidence for various Karyopherins, nucleoporins, 
and the dynein light chain km23-2 in Smad3 trafficking (Hill, 2009; 
Jin et al., 2009), it is still not settled how R-Smads are translocated 
to the nucleus or whether distinct mechanisms are used by Smad2 
and Smad3.
While the manner by which the Smad proteins traffic from the 
cytoplasm to the nucleus is unresolved, the sorting nexins (SNXs) are 
one family (>30 in human) of structurally related trafficking proteins 
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SNX9 is required for Smad3 nuclear import
SNX9 is essential for the endocytosis of various cargoes (Lundmark 
and Carlsson, 2009). As TGFβ-stimulated Smad2/3 phosphorylation 
occurs downstream of dynamin action (Hayes et al., 2002; Penheiter 
et al., 2002; Di Guglielmo et al., 2003), it seemed reasonable that 
SNX9 might modulate TGFβ signaling through specific inhibition of 
Smad3 phosphorylation. Contrary to our expectations, no difference 
in either the kinetics or extent of R-Smad phosphorylation was ob-
served in SNX9 KD or DN clones relative to control (Figures 2, A and 
B, and Supplemental Figure S1D). Because R-Smad phosphorylation 
enhances their nuclear accumulation (Feng and Derynck, 2005; 
Schmierer and Hill, 2007; Hill, 2009), we next investigated whether 
SNX9 was required for Smad3 nuclear import. While SNX9 loss sig-
nificantly reduced nuclear Smad3 following addition of TGFβ, nu-
clear Smad2 was unaffected (Figure 2C). Quantitation of this re-
sponse demonstrated an approximate 50–60% decrease in the 
nuclear accumulation of Smad3 with no appreciable effect on Smad2 
or basal nuclear R-Smads (Figure 2D). This finding was further sup-
ported using DN-SNX9 constructs. Consistent with the loss in nu-
clear Smad3 observed in the KD cells, DN-SNX9 specifically pre-
vented ligand-stimulated Smad3 nuclear delivery (Supplemental 
Figure S1E).
SNX9 specifically impacts phosphorylated Smad3 
nuclear entry
While it has been suggested that R-Smad nuclear accumulation is 
due primarily to retention of phosphorylated over nonphosphory-
lated R-Smads (Schmierer and Hill, 2005, 2007), other studies have 
also observed increased rates of R-Smad nuclear trafficking in stim-
ulated versus unstimulated cells (Kurisaki et al., 2001; Schmierer 
et al., 2008). To address these issues in vivo without the complica-
tion of unknown ratios of unphosphorylated to phosphorylated 
Smad3 produced after ligand stimulation, we generated a Smad3 
construct fused to the cell-transducing TAT domain from HIV 
(Becker-Hapak et al., 2001), labeled the purified protein with 125I, 
and phosphorylated half with the immunopurified/activated type I 
TGFβ receptor (TβRI) before it was added to mesenchymal cells that 
then underwent nuclear purification. After normalizing for initial 
cellular uptake (Supplemental Figure S2), we observed clear differ-
ences in both the kinetics of nuclear import as well as retention 
between TAT-pSmad3 and TAT-Smad3 (Figure 3A, top panel). For 
instance, while half-maximal nuclear translocation of TAT-pSmad3 
occurred within ∼20 min, unphosphorylated TAT-Smad3 was 
∼3.5 times slower. Furthermore, consistent with a role for Smad 
phosphorylation in also enhancing nuclear retention, the rate of 
TAT-pSmad3 and TAT-Smad3 nuclear loss was 28.6 counts/min and 
235.7 counts/min, respectively, which was unaffected by SNX9 KD 
(i.e., corresponding rates of 26.6 counts/min and 211.8 counts/
min). Consistent with the analyses shown in Figure 2, C and D, and 
Supplemental Figure S1E, while SNX9 loss had no appreciable ef-
fect on unphosphorylated TAT-Smad3 (i.e., basal shuttling), it sig-
nificantly inhibited TAT-pSmad3 nuclear accumulation (Figure 3A, 
middle and bottom panels, respectively). Thus, while the TAT pep-
tides allow one to differentiate the rate of basal Smad3 shuttling 
from pSmad3 nuclear import, they also confirm the importance of 
phosphorylation on Smad3 nuclear retention and the need for 
SNX9 in promoting pSmad3 nuclear entry.
SNX9 preferentially binds phosphorylated Smad3
As the preceding data define a new role for SNX9 in mediating 
Smad3 nuclear transport and biological action, we addressed 
the following mechanistic questions. First, does SNX9 show 
with proposed roles in receptor degradation, sorting, internaliza-
tion, and recycling (Carlton et al., 2005; Badour et al., 2007; Verges, 
2007). All SNXs are defined by the presence of a phox homology 
(PX) domain that binds phosphoinositides and aids in targeting 
SNXs to particular membranes (Worby and Dixon, 2002). SNX9, 
however, also contains an amino terminal SH3 domain required for 
dynamin, cdc42-associated kinase (ACK2), WASp, and Itch binding; 
a Bin/Amphiphysin/Rvs (BAR) domain that senses membrane curva-
ture and is required for dimerization; and a low-complexity region 
that binds AP-2α and clathrin (Supplemental Figure S1A; Worby and 
Dixon, 2002; Carlton et al., 2005; Badour et al., 2007; Lundmark and 
Carlsson, 2009; Baumann et al., 2010). Because SNX9 is known to 
modulate the trafficking responses of several transmembrane recep-
tors (Worby and Dixon, 2002; Verges, 2007), and Smad phosphory-
lation has been shown to be coupled to TGFβ endocytic activity in 
various systems (Hayes et al., 2002; Penheiter et al., 2002; Di 
Guglielmo et al., 2003), studies were initiated to examine the role(s) 
of SNX9 in TGFβ receptor action. Although we found negligible 
effects on receptor activity, we show that SNX9 has an obligate role 
in the cellular response to TGFβ and differentially regulates Smad3- 
from Smad2-dependent phenotypes. The results expose a new role 
for SNX9 downstream of its canonical plasma membrane action and 
define a mechanism by which specificity in profibrotic TGFβ signal-
ing can be controlled through SNX9 promoting Smad3 nuclear 
import following ligand-induced phosphorylation.
RESULTS
SNX9 specifically regulates Smad3-dependent 
TGFβ signaling
TGFβ receptor (TGFβR) signaling has been shown to be intimately 
connected to the cellular trafficking machinery in various systems 
(Hayes et al., 2002; Penheiter et al., 2002; Di Guglielmo et al., 
2003). As SNX9 is known to function at similar plasma membrane 
and endosomal locales (Verges, 2007; Cullen, 2008; Lundmark and 
Carlsson, 2009), studies were initiated to determine whether SNX9 
had a role in the mesenchymal cell response to TGFβ. AKR-2B 
clones expressing two distinct SNX9 short hairpin RNAs (shRNAs) or 
dominant-negative (DN)-SNX9 constructs were isolated, and the 
ability of TGFβ to stimulate anchorage-independent growth (AIG) 
was determined (Supplemental Figure S1A provides a schematic of 
SNX9 and the dominant negatives). Although basal growth was un-
affected, ligand-induced AIG was reduced to control levels by 
SNX9 knockdown (KD) or DN expression (Figure 1A and Supple-
mental Figure S1B). TGFβ also has a major role in cell migration and 
wound repair (Rahimi and Leof, 2007; Barrientos et al., 2008). Anal-
ogous to that observed for AIG, SNX9 KD significantly impaired the 
in vitro migratory action of TGFβ (Figure 1B).
As Figure 1, A and B, and Supplemental Figure S1B documented 
that two TGFβ phenotypes studied in fibroproliferative models were 
dependent on SNX9, we next investigated whether Smad tran-
scriptional responses displayed a similar SNX9 requirement. Initial 
studies showed a 50–70% reduction from transfected Smad3-depen-
dent reporters (3TP or SBE), yet no effect on Smad2-regulated Activin 
response element (ARE) signaling (Figure 1C and Supplemental 
Figure S1C). Because this was quite surprising, qPCR evaluation of 
three endogenous Smad2- or Smad3-responsive genes was under-
taken. While none of the Smad2-responsive genes were inhibited, 
reduction in each of the Smad3-responsive genes was observed 
(Figure 1D). In fact, for two of the three Smad2-responsive genes, 
there was a statistically significant increase with reduced SNX9, likely 
reflecting positive and negative actions of Smad2 and Smad3, re-
spectively (Labbe et al., 1998).
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(NIH3T3 and WI38) and epithelial (NMuMG and EpH4) cell lines 
(Figure 3D).
Figure 3, B and C, shows that a SNX9/Smad2 association cannot 
be observed either in vivo or in vitro. To address the possibility that 
Smad2 has a role in promoting and/or enhancing SNX9/Smad3 
binding, we performed the studies provided in Figure 4A. In the 
absence of Smad2, there was ligand-dependent SNX9/Smad3 
binding similar to that seen in AKR-2B cells. Because the canonical 
model of R-Smad nuclear translocation has Smad4 present to gen-
erate the most energetically favorable heterotrimer (Wu et al., 2001; 
Chacko et al., 2004), we determined the requirement for SNX9 or 
Smad4 in the formation of either the pSmad3/Smad4 or pSmad3/
SNX9 complex (Figure 4, B and C); no identifiable role for either 
SNX9 or Smad4 was observed.
The co-IP and GST pull-down data depicted in Figures 3, B–D, and 
4, A and C, show a pSmad3/SNX9 interaction in multiple murine and 
human cell lines. Because this indicated a novel role for a member of 
the SNX family, it was further confirmed using immunofluorescence 
differential R-Smad binding, is this regulated by ligand, and is 
there any identifiable role for Smad4? Second, is SNX9 required 
for importin (Imp) and/or nucleoporin (Nup) binding to Smad3? 
Third, how does SNX9 function to promote pSmad3 nuclear 
import?
For investigation of the first of these issues, AKR-2B cells 
were stimulated with TGFβ, and the ability of SNX9 to coimmu-
noprecipitate Smad2 or Smad3 was determined. While a slight 
basal association with Smad3 was observed, addition of ligand 
enhanced the interaction (Figure 3B). In contrast, no binding 
of SNX9 and Smad2 could be detected basally or following 
TGFβ treatment. This interaction of SNX9 with pSmad3 was 
further confirmed using glutathione S-transferase (GST)-Smad2 
or GST-Smad3 fusion proteins (Figure 3C). Analogous to co-
immunoprecipitation (co-IP), SNX9/R-Smad binding was only 
observed with GST-pSmad3. Furthermore, the SNX9/pSmad3 
association shown in AKR-2B cells (Figure 3, B and C) was addi-
tionally documented in two other nontransformed mesenchymal 
FIGURE 1: SNX9 regulates TGFβ-stimulated soft-agar colony formation, wound closure, and Smad3-dependent 
transcriptional activity. (A) AKR-2B cells stably integrated with nontargeting (NT) or SNX9 shRNA were seeded in soft 
agar in the absence (−) or presence (+) of 10 ng/ml of TGFβ. Data depict the number of colonies from two pooled NT 
(A-NT.8 and A-NT.10), four pooled SNX9 shRNA1 (shSNX9; A-77.1, A-77.2, A-77.7, and A-77.11), and four pooled SNX9 
shRNA2 (Alt-shSNX9; A-78.1, A-78.2, A-78.5, and A-78.6) clones. Inset shows SNX9 knockdown. (B) Scratch assays were 
performed on NT (A-NT.8) and SNX9 KD (A-77.11) clones as described in Materials and Methods and are representative 
of three separate experiments. Red bands indicate the leading edge after 24 h in the presence or absence of TGFβ. 
(C) NT or SNX9 KD AKR-2B cultures were transfected with the indicated luciferase reporters and either left untreated 
(−) or stimulated (+) with TGFβ for 24 h. Data are from three independent experiments (A-NT.8 and pooled data from 
A-77.7 and A-77.11 clones) and represent the mean fold induction ± SD relative to untreated. (D) A-NT.8 or A-77.7 cells 
were arrested and treated (+) for 6 h with TGFβ. RNA was isolated and qPCR performed for the indicated Smad2- or 
Smad3-dependent targets. Data reflect the normalized fold induction above unstimulated NT controls ± SD (n = 3). 
* denotes significant difference between stimulated NT and shSNX9 cultures.
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SNX9 requirements for nuclear 
membrane association
As SNX9 has a role in pSmad3 nuclear im-
port (Supplemental Figure S1E and Figures 
2, C and D, and 3A), we investigated 
1) whether SNX9 bound and/or traversed 
the nuclear membrane; and 2) the cis and 
trans requirements for the SNX9/pSmad3 
complex to bind and/or undergo nuclear 
translocation. While TGFβ stimulated the 
association of SNX9 and pSmad3 with the 
nuclear membrane, only pSmad3 entered 
the nucleus and bound chromatin (Figure 5D). 
Because SNX9 shows minimal nuclear mem-
brane binding in the absence of TGFβ treat-
ment (Figure 5D), yet is necessary for pS-
mad3 nuclear trafficking (Supplemental 
Figure S1E and Figures 2, C and D, and 3A), 
suggests, first, that Smad3 would be re-
quired for SNX9 nuclear membrane bind-
ing; and second, in the absence of Smad3, 
negligible SNX9 would associate with the 
nuclear membrane following addition of 
TGFβ. As shown in Figure 5E, although 
SNX9 associated with the nuclear mem-
brane following TGFβ stimulation, binding 
also required expression of Smad3. These 
biochemical findings were further confirmed 
by transfecting yellow fluorescent protein 
(YFP)-SNX9 into Smad2 or Smad3 KD cells 
(Figure 5F; Andrianifahanana et al., 2010). 
While TGFβ induced a perinuclear distribu-
tion for YFP-SNX9 dependent on Smad3, 
this occurred independent of Smad2 ex-
pression, and no evidence for YFP-SNX9 
undergoing nuclear import was observed 
(Figure 5, C and F).
As trafficking functions of the SNXs have 
been shown to be dependent on both 
phosphoinositide binding (Yarar et al., 2008) 
and homodimerization (Childress et al., 
2006), we investigated whether analogous 
SNX9 motifs were required for Smad3 nu-
clear recruitment and Smad3-regulated 
responses. SNX9 KD cells were transfected 
with shRNA-resistant wild type (WT)-SNX9 
or escape constructs harboring either point 
mutations in the PX and BAR domain motifs 
required for high-avidity PIP2 binding (Yarar 
et al., 2008) or a truncation of the carboxyl-
terminal 13 amino acids required for ho-
modimerization (Childress et al., 2006). 
While the WT SNX9 escape construct 
(escWT) and homodimerization mutant 
(escΔ13C) both colocalized with Smad3 in a 
perinuclear locale following TGFβ treat-
ment, the PIP2 mutant (escMUTPIP2) showed 
only diffuse cytoplasmic staining (Figure 6A). These findings pro-
vided the first indication that PIP2 binding and homodimerization 
could be uncoupled from SNX9 action. The interactions with 
pSmad3 and the nuclear membrane were further established 
biochemically. As shown in Figure 6B, although pSmad3 nuclear 
microscopy. As shown in Supplemental Figure S3 and Figure 5, A–C, 
SNX9 and Smad3 colocalize within a similar perinuclear compartment 
following treatment with TGFβ. The increased colocalization ranged 
from 2.6-fold (NIH3T3) to 8.5-fold (NMuMG), with a significant in-
crease observed in all lines (Figure 5B).
FIGURE 2: SNX9 functions downstream of R-Smad phosphorylation. (A) AKR-2B clones 
expressing nontargeting (NT) or SNX9 shRNA were left untreated (0) or stimulated with TGFβ. 
Western blot analysis was performed for the indicated phosphorylated (pSmad2, pSmad3) or 
total (Smad2/3, GAPDH) proteins. (B) Quantitation of pSmad2 (n = 9) or pSmad3 (n = 11) at each 
time compared with NT and normalized to GAPDH. The quantitation of the 20- and 30-min time 
points shown in A were pooled and are presented as 20 & 30 (pool). (C) NT (A-NT.8) or SNX9 KD 
(A-77.11) cells were stimulated in the absence (−) or presence (+) of TGFβ for 45 min, and 
Smad2 or Smad3 immunofluorescence was determined. (D) Quantitation of nuclear R-Smad 
staining ± SD from 20 cells in each of two experiments from C. The y-axis represents the nuclear 
pixel signal obtained with 100%, defined as the signal from 7 A-NT.8 cells that showed no 
cytoplasmic R-Smad staining following TGFβ stimulation. * denotes significant difference 
between stimulated NT and shSNX9 cultures.
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the SNX9 WT and mutant escape constructs 
to reconstitute canonical SNX9 action and/
or Smad3-dependent signaling (Figure 6, 
C–E). Although re-expression of WT SNX9 
enhanced basal dynamin GTPase activity, 
neither the PX/BAR nor the dimerization 
mutant possessed this capability (Figure 6C). 
This is consistent with previous publications 
(Childress et al., 2006; Yarar et al., 2008) 
and reflects established SNX9 function. In 
contrast, while escWT- and escΔ13C-SNX9 
reconstituted Smad3-dependent 3TP-lucif-
erase activity and soft-agar colony forma-
tion, this was not observed with the PX/BAR 
mutant (Figure 6, D and E).
SNX9 is required for Smad3/Imp8 
complex formation
Prior studies have reported roles for the im-
portins (Imp7, Imp8, and Impβ) and/or nucleo-
porins (Nup153 and Nup214) in pSmad3 nu-
clear translocation (Xiao et al., 2000; Kurisaki 
et al., 2001; Xu et al., 2002, 2007; Yao et al., 
2008). Because we identified a similar function 
for SNX9, we evaluated whether these find-
ings might be related. As shown in Figure 7A, 
ligand-dependent binding of Imp8 and SNX9 
was observed with similar kinetics to that 
observed for the SNX9/Smad3 association 
(Figure 3B). In contrast, no significant binding 
of Imp7 or Impβ with SNX9 could be detected 
(Figure 7A). Owing to difficulties immuno-
precipitating endogenous nucleoporins, we 
transiently transfected hemagglutinin (HA)-
tagged Nup153 and Nup214 and examined 
the ability of these to coimmunoprecipitate 
with SNX9. No binding between SNX9 and 
either Nup153 or Nup214 was observed 
(Supplemental Figure S4, A and B).
The TGFβ-induced association of SNX9 
with Imp8 and pSmad3 indicates that 
Smad3 nucleocytoplasmic shuttling is even 
more complex than previously thought. To 
further address that issue, we investigated 
the Smad3, SNX9, and/or Imp8 requirement 
to generate SNX9/Imp8, Smad3/Imp8, or 
SNX9/Smad3 complexes (Figure 7, B and C). 
While the absence of Smad3 prevented the 
association of SNX9 with Imp8 (Figure 7B, 
compare lanes 2 and 6 in panel 1), and loss 
of SNX9 significantly diminished the forma-
tion of Smad3/Imp8 complexes (Figure 7B, 
compare lanes 2 and 4 in panel 3), knock-
down of Imp8 had minimal impact on SNX9/
Smad3 association (Figure 7C, compare 
lanes 2 or 4 with 6 in panel 1).
Imp8 links pSmad3 to Impβ for nuclear entry.
The requirement for Impβ family members (i.e., Impβ and Imp8) in 
R-Smad nuclear import is unsettled. For instance, 1) there are re-
ports both indicating (Xiao et al., 2000; Kurisaki et al., 2001) as 
well as rejecting (Xu et al., 2003, 2007) a need for Impβ; and 2) it 
membrane binding is dependent on SNX9, it is independent of 
SNX9 homodimerization but requires SNX9 binding motifs for PIP2.
Figure 6, A and B, indicates that the action of SNX9 in pSmad3 
signaling is distinct from its conventional role(s) in regulating intra-
cellular trafficking. This was confirmed by assessing the ability of 
FIGURE 3: SNX9 specifically binds and is required for enhanced pSmad3 nuclear entry. 
(A) [125I]-labeled TAT-Smad3 and TAT-pSmad3 proteins were generated as described in Materials 
and Methods. AKR-2B cells expressing nontargeting (NT) shRNA (A-NT.8) or shRNA against 
SNX9 (shSNX9; A-77.7) were transduced with the indicated TAT peptides, and 125I counts in total 
cell and nuclear lysates were obtained from 10 to 270 min. Data reflect the mean ± SD from 
three experiments for the 30- to 240-min time points and from two experiments for the 10-, 
20-, and 270-min time points. (B) AKR-2B cells were stimulated with TGFβ, and the indicated 
proteins coprecipitating with SNX9 were detected by Western blotting (top three panels). 
Bottom five panels: indicated proteins in total lysate. (C) AKR-2B lysates were incubated with 
GST or GST-Smad fusion protein untreated or in vitro phosphorylated by TβRI. Bound SNX9 (top 
panel) and the phosphorylated R-Smad (second panel) used in the pull down were detected 
using SNX9 and phospho-Ser/Thr antibodies, respectively. (D) Cell lines were stimulated in the 
absence (−) or presence (+) of TGFβ for 60 min. Following lysis and GST-SNX9 pull down, 
Western blotting was performed. Bottom panel depicts pSmad3 expression in total cell lysate.
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and Smad3 with SNX9, Imp8, and/or Impβ 
(Figure 7D). While SNX9, Smad3, and 
Imp8 showed the TGFβ-dependent inter-
actions depicted in Figures 3–5 and 7, and 
previously documented (Strom and Weis, 
2001), Imp8/Impβ heteromers were readily 
observed and Impβ bound both Smad2 
and Smad3 with ligand increasing the as-
sociation. The functional significance of 
this interaction was addressed in Figure 8, 
A and B. Although Impβ KD abrogated 
TGFβ-stimulated as well as basal nuclear 
import of Smad2 and Smad3, SNX9 or 
Imp8 KD specifically prevented ligand-
induced Smad3 nuclear accumulation, fur-
ther documenting that basal and stimu-
lated Smad import are distinctly regulated 
(Figures 3A, 7, and 8, A and B; Xu et al., 
2007; Yao et al., 2008).
The preceding data (Supplemental 
Figure S1E and Figures 2D, 3A, and 8B) 
demonstrate a requirement for SNX9, 
Imp8, and/or Impβ in pSmad3 nuclear en-
try. It does not address whether each blocks 
pSmad3 trafficking at defined sites. For in-
vestigating this further, KD cells were 
treated with TGFβ, and the association of 
pSmad2 or pSmad3 with the nuclear mem-
brane, crude nuclear pore, or soluble nu-
clear fraction was determined. As expected, 
pSmad2 was unaffected by SNX9 or Imp8 
KD (i.e., found in all fractions) and was only 
excluded from the soluble nuclear fraction 
in the absence of Impβ (Figure 8C). This is 
consistent with pSmad2 activity/trafficking 
being independent of SNX9 or Imp8 
(Figures 1–3, 7D, 8, A and B, and Supple-
mental Figure S1) yet requiring Impβ for 
translocation through the nuclear pore 
(Figures 8, A–C). While a similar block was 
observed for pSmad3 in Impβ KD cells, loss 
of SNX9 or Imp8 had distinct phenotypes. 
Although SNX9 KD prevented pSmad3 as-
sociation with the nuclear membrane (Sup-
plemental Figure S5 and Figures 6B and 
8C), the absence of Imp8 (which had no ef-
fect on pSmad3 nuclear membrane bind-
ing) abrogated pSmad3 entry into the nu-
clear pore and subsequent translocation 
(Supplemental Figure S5 and Figure 8C). A 
model to help put these findings in context 
is proposed in Figure 8D.
DISCUSSION
As the majority of TGFβ-regulated R-Smad 
transcriptional activity and biological ac-
tion is associated with Smad3 (Feng and 
Derynck, 2005), it would seem likely that 
mechanisms exist that distinguish Smad3 from Smad2 nuclear 
trafficking. The importance of that question is best exemplified for 
kidney fibrosis and skin cancer, for which it has been documented 
that, while Smad3 signaling is profibrotic/procarcinogenic, Smad2 
was surprising that we found no effect of Imp8 KD on SNX9/pS-
mad3 binding (Figure 7C), since Imp8 could be coprecipitated 
with both proteins following TGFβ treatment (Figure 7, A and B). 
To address these issues, we determined the interrelation of Smad2 
FIGURE 4: pSmad3/SNX9 binding is independent of Smad2 or Smad4. (A) Smad2−/− and 
Smad3−/− null MEFs were transfected (+) with SNX9-Myc, Smad2-GFP, and/or Smad3-GFP and 
either left untreated (−) or stimulated (+) with TGFβ for 30 min. Co-IPs were performed using 
antisera to the Myc epitope tag (panels 1–4), Smad2 (panel 5), or Smad3 (panel 6); and samples 
were Western blotted for GFP (panels 1 and 3), Smad2 (panel 2), Smad3 (panel 4), or Myc 
(panels 5 and 6). Bottom seven panels: Western analysis was performed as above, except the 
Smad and SNX9 fusion proteins were detected using antisera to GFP or Myc, respectively. 
(B) Parental AKR-2B cells (AKR) and clones expressing nontargeting or SNX9 shRNA and two 
SNX9 DN lines were stimulated for 30 min with TGFβ and lysates immunoprecipitated with 
antisera to Smad4. Following Western transfer, the membrane was probed with antibodies to 
pSmad3 and Smad4. The bottom three panels depict expression of the indicated proteins in 
total cell lysate. (C) AKR-2B fibroblasts (AKR) and Smad4 KO (−/−) MEFs were left untreated 
(−) or stimulated (+) with TGFβ for 30 min before SNX9 immunoprecipitation. Following Western 
blotting, the membrane was probed for pSmad3 or SNX9. The remaining five panels depict 
expression of the indicated proteins in total cell lysate.
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R-Smad proteins are known to continu-
ously shuttle between the cytoplasm and 
nucleus (Inman et al., 2002; Xu et al., 2002; 
Schmierer and Hill, 2005), however, upon 
TGFβ stimulation the ratio of cytoplasmic 
to nuclear R-Smads decreases dramatically. 
Mechanisms of increased nuclear traffick-
ing (Kurisaki et al., 2001; Chen et al., 2005; 
Schmierer and Hill, 2007), increased nu-
clear retention (Inman et al., 2002; Nicolas 
et al., 2004; Schmierer and Hill, 2005), or a 
combination thereof could all account for 
this, and evidence exists supporting each 
(Schmierer et al., 2008). To further investi-
gate whether Smad phosphorylation im-
pacts the rate of nuclear import, we used a 
new approach based on the cell-penetrat-
ing activity of the HIV TAT peptide (Becker-
Hapak et al., 2001; Sawant and Torchilin, 
2010; Arif et al., 2014). We reasoned that in 
the context of a system in which basal (i.e., 
constitutive) nuclear shuttling of nonphos-
phorylated Smad3 occurs, immunofluores-
cence (or Western blotting) is not designed 
to address whether phosphorylation (i.e., 
inducible) affects the kinetics of nuclear im-
port, as it is difficult to determine time 0 
(i.e., “start”) for a pool of nonphosphory-
lated Smad3 in a constitutive system. Fur-
thermore, even though adding ligand 
would give a time 0 for phosphorylated 
Smad3, it routinely takes ∼20–30 min for 
sufficient pSmad3 to be detected. In con-
trast, TAT peptides allow one to quantita-
tively assess similarly synchronized and 
normalized pools of phosphorylated and 
nonphosphorylated Smad3. As shown in 
Figure 3A, when normalized for initial up-
take, phosphorylated TAT-Smad3 (i.e., 
analogous to ligand stimulated) entered 
the nucleus ∼3.5 times faster than non-
phosphorylated TAT-Smad3 (i.e., analo-
gous to basal shuttling). Moreover, in 
agreement with a number of studies 
(Hill, 2009), 1) both phosphorylated and 
nonphosphorylated TAT fusions underwent 
nuclear translocation; and 2) increased 
nuclear retention of phosphorylated TAT-
Smad3 was observed. Thus, while TAT-
Smad3 peptides provide a new methodol-
ogy to further address some of these 
unresolved issues, they independently con-
firm canonical findings regulating R-Smad 
action. Our determination that SNX9 func-
tions to both regulate and provide specific-
ity for this process should hopefully help 
clarify this issue.
The SNXs represent a family of proteins with diverse functions 
(Verges, 2007; Cullen, 2008; Lundmark and Carlsson, 2009). Be-
cause earlier work documented an association of SNXs 2, 4, and 
6 with type I and type II TGFβ receptors (Parks et al., 2001), and 
SNX9 is known to function at both the plasma membrane and the 
is antifibrotic/anticarcinogenic (Hoot et al., 2008; Meng et al., 
2010). Thus, rather than designing studies to simply “inhibit TGFβ 
signaling,” in the current study, we provide evidence that target-
ing the SNX/pSmad3 interaction could provide a means to di-
rectly impact Smad3-dependent pathologies.
FIGURE 5: TGFβ induces perinuclear SNX9/pSmad3 colocalization and nuclear membrane 
binding. (A) AKR-2B cells were transduced with HA-TAT-SNX9 protein (0.8 μM) for 90 min. 
After transduction and treatment with TGFβ for 60 min, TAT-SNX9 and endogenous Smad3 
were detected by immunofluorescence analysis. Nuclei were stained with DAPI. (B) AKR-2B, 
NIH3T3, WI38, NMuMG, and EpH4 cells were treated as above, except stimulation with 
TGFβ was for 45 min for all lines other than AKR-2B. Colocalization of TAT-SNX9 and Smad3 
was determined from 20 cells in each of two experiments ± SD. * denotes significant 
difference from unstimulated cultures of the same cell type. (C) Following YFP-SNX9 
transfection, AKR-2B cells were treated in the absence (−) or presence (+) of TGFβ for 45 min 
and stained for Smad3 as described in Materials and Methods. Cell outline is shown in the 
YFP-SNX9 panels, and the inset shows an additional microscopic field. The YFP signal was 
pseudocolored green to enable observation of any colocalization when overlaid with Smad3. 
(D) AKR-2B cells were left untreated (0) or stimulated with TGFβ and processed for nuclear 
membrane, soluble nuclear, or chromatin-associated proteins. (E) Analogous study as in D 
was performed on quiescent (−) and 30-min TGFβ-treated (+) AKR-2B (AKR) cells and Smad3 
null MEFs (Smad3−/−). (F) Smad2 or Smad3 knockdown (KD) AKR-2B cells were transfected 
with YFP-SNX9 and treated as in C before fixation and confocal microscopy. Inset reflects an 
additional microscopic field, and the bottom figure documents appropriate loss of pSmad 
signaling in the knockdowns.
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SNX9 was found to preferentially bind and/or colocalize with 
phosphorylated Smad3 in vivo by co-IP or transfection of epitope-
tagged SNX9 and in vitro using GST pull down in a number of cell 
types (Figures 3, B–D, 4, A and C, 5, A–C and F, 6A, and 7, C and D, 
and Supplemental Figure S3). When direct association, however, 
was assessed using in vitro–generated SNX9 and phosphorylated 
GST-Smad3, no interaction could be detected (unpublished obser-
vations). While this could simply reflect the significant technical is-
sues associated with such an in vitro approach, it might also indicate 
the requirement for a higher-order complex. Although these two 
possibilities are not mutually exclusive, and we are examining that 
issue, in this initial study, we investigated two relevant possibilities. 
First, would SNX9/pSmad3 binding only occur in the context of a 
heteromeric R-Smad interaction (i.e., also require Smad2 and/or 
Smad4); and second, might this reflect a need for a previously iden-
tified importin or nucleoporin implicated in R-Smad nuclear 
import?
To address the first question, we performed studies in Smad2, 
Smad3, and Smad4 null mouse embryo fibroblasts (MEFs; Figure 4). 
early endosome (Lundmark and Carlsson, 2009), studies were ini-
tiated to determine whether these findings were related. Con-
trary to our expectations, while loss of SNX9 had only minimal 
effect on either R-Smad phosphorylation (Supplemental Figure 
S1D and Figure 2, A and B) or TGFβ receptor internalization 
(unpublished observations), Smad3-dependent signaling (Sup-
plemental Figure S1C and Figure 1, C and D) as well as nuclear 
membrane binding (Supplemental Figure S5, A and B, and 
Figures 6B and 8C) was significantly diminished. Of particular 
note, Smad3 signaling, SNX9 attaining a perinuclear locale, and 
pSmad3 nuclear association occurred independent of SNX9 ho-
modimerization but required the ability to bind phosphoinositi-
des (Figure 6). In that SNX9 homodimerization (in conjunction 
with phosphoinositide binding) has been reported to be essential 
for correct plasma membrane/early endosome targeting, dyna-
min binding, and cargo endocytosis (Soulet et al., 2005; Childress 
et al., 2006; Yarar et al., 2008; Lundmark and Carlsson, 2009), 
these results separated SNX9’s canonical functions from its role in 
pSmad3 signaling.
FIGURE 6: Nuclear membrane association of pSmad3/SNX9 is dependent on phosphoinositide binding motifs in 
SNX9 and independent of SNX9 homodimerization. (A) SNX9 KD A-77.11 cells were transfected with the indicated 
Myc-tagged SNX9 escape constructs, treated in the absence (−) or presence (+) of TGFβ for 45 min, and stained for 
Smad3 or Myc-SNX9. Nuclei were stained with DAPI; the inset shows an additional transfected cell. (B) Following 
A-77.11 cell (shSNX9) transfection and TGFβ treatment as in A, total cell lysate and nuclear membrane preparations 
were Western blotted for the indicated proteins. (C) Dynamin GTPase assay was performed as described in Materials 
and Methods on SNX9 KD A-77.7 cells alone or transfected with the escape constructs as in A. Data reflect mean ± SD 
GTPase activity from three experiments. (D) SNX9 KD A-77.7 cells were transiently transfected with the Smad3-
regulated (3TP) luciferase reporter alone or in conjunction with the indicated escape constructs. Cells were either left 
untreated (−) or stimulated (+) with TGFβ for 24 h, and normalized luciferase activity was determined. Data represent 
the mean fold induction ± SD relative to untreated from four experiments. (E) SNX9 KD A-77.7 cells were transiently 
transfected as in A, and fold soft-agar colony induction relative to no TGFβ from four experiments was determined as in 
Figure 1A. * denotes statistical difference from TGFβ-treated shSNX9 cells.
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and nucleoporins could be coprecipitated 
with SNX9 following addition of TGFβ. Such 
an interaction was observed only with Imp8 
(Supplemental Figure S4, A and B, Figure 7, 
A, B, and D), supporting previous work sug-
gesting that Imp8 is required for nuclear 
import of Smad3 in stimulated cells (Xu 
et al., 2007). Of particular note was that, in 
the absence of SNX9, we were not only un-
able to co-IP Imp8 with pSmad3 (Figure 7B), 
but pSmad3 was not associated with the 
nuclear membrane (Supplemental Figure 
S5 and Figures 6B and 8C). This is in con-
trast to studies using Imp8 KD cells, in 
which no detectable impact on SNX9/
pSmad3 binding (Figure 7C) or association 
with the nuclear membrane was observed 
(Supplemental Figure S5 and Figure 8C). 
These findings suggest that SNX9 func-
tions to promote the interaction of pSmad3 
with Imp8 by recruiting it to the nuclear 
membrane. However, although Imp8 can 
associate with SNX9 and Impβ (Figure 7, A, 
B, and D), SNX9 is never found with Impβ 
(Figure 7, A and D), indicating that the for-
mation of pSmad3/SNX9 and pSmad3/
Impβ complexes may be mutually exclu-
sive. Collectively, these data suggest 
nuclear delivery of pSmad3 occurs sequen-
tially whereby, first, SNX9 is necessary for 
pSmad3 nuclear membrane binding and 
presentation to Imp8; second, Imp8 pro-
motes pSmad3 complexing with the nu-
clear pore machinery; and third, Impβ is 
required for pSmad3 translocation through 
the nuclear pore (Figure 8D).
In summary, we provide evidence that 
SNX9 is involved in Smad3 (but not Smad2) 
signaling and acts as an adaptor for the nu-
clear translocation of pSmad3. As the major-
ity of TGFβ-regulated transcriptional activity 
and biological action is associated with 
Smad3, the ability to specifically impact 
Smad3-dependent phenotypes would pro-
vide a previously unavailable degree of 
specificity to modulate and/or treat various 
TGFβ-dependent disorders.
MATERIALS AND METHODS
Cell lines and constructs
The following cell lines were used: murine AKR-2B (mesenchymal), 
NIH3T3 (mesenchymal), NMuMG (mammary epithelial), and EpH4 
(mammary epithelial), and human WI38 lung fibroblasts. Cultures 
were grown in DMEM supplemented with 10% fetal bovine serum 
(FBS) and stimulated with 5 ng/ml TGFβ unless stated otherwise.
For assessing the effect of DN-SNX9 expression on TGFβ re-
sponses, A105 cells (an AKR-2B subclone expressing endogenous 
and chimeric TGFβ receptors consisting of the ligand-binding domain 
of the GM-CSF alpha or beta receptors fused to the transmembrane 
and cytoplasmic domain of TβRI and TβRII, respectively, generated to 
investigate aspects of TGFβ receptor trafficking; Anders et al., 1997, 
1998) were stably cotransfected with pBabe-Puro and the indicated 
Although an obligate requirement for Smad3 was observed, neither 
the presence nor absence of Smad2 or Smad4 had any detectable 
impact on the coprecipitation of SNX9 and Smad3 following TGFβ 
treatment. While this supports the hypothesis that SNX9 can regu-
late homomeric pSmad3 complexes, heteromeric complexes con-
taining pSmad3 and Smad4 are just as likely to be regulated by 
SNX9, as the heterotrimer (consisting of two pSmad3s and a single 
Smad4 molecule) represents the most energetically favorable struc-
ture (Chacko et al., 2004).
Investigating the second possibility, however, is somewhat more 
problematic, as evidence supports a role(s) for Imp7, Imp8, Impβ, 
Nup153, and/or Nup214 in R-Smad nuclear entry (Xu et al., 2002; 
Moustakas and Heldin, 2008; Yao et al., 2008; Hill, 2009). As such, 
we determined whether any of the aforementioned importins 
FIGURE 7: SNX9 is required for pSmad3/Imp8 binding, but SNX9/pSmad3 association is 
independent of Imp8. (A) AKR-2B cells were stimulated with TGFβ and immunoprecipitated (IP) 
with the indicated importin (Imp) antibodies. Following Western transfer (WB), the membrane 
was probed for associated SNX9 (first three panels) or the immunoprecipitated protein (panels 
4–6). In the bottom seven panels, total cell lysate was immunoblotted for the indicated targets. 
(B) AKR-2B cells stably expressing nontargeting (NT; A-NT.8) or SNX9 shRNA (shSNX9; A-77.7) 
and Smad3 null MEFs (Smad3−/−) were left untreated (−) or stimulated with TGFβ for 30 min. 
Cultures were lysed and immunoprecipitated for SNX9 or Smad3 before Western analysis for 
bound Imp8, SNX9, or Smad3. Remaining panels show expression of the indicated 
phosphorylated (p) or total protein in total cell lysate. (C) AKR-2B cells (AKR) or clones stably 
expressing nontargeting (NT) or Imp8 (shImp8) shRNA were treated as in B. Following SNX9 IP, 
coprecipitating Smad3 or SNX9 was determined. Remaining panels depict expression of the 
indicated proteins in total cell lysate. (D) AKR-2B cells were treated as in B. Lysates were 
immunoprecipitated with SNX9, Imp8, or Impβ antibodies and probed for the indicated targets.
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ViraPower reagents (Invitrogen, Carlsbad, 
CA) as described by the manufacturer. Fol-
lowing a 72-h incubation, viruses were har-
vested and added to AKR-2B plated at 2.5 × 
105 cells/six-well plate. The medium was 
changed the following day, and 48 h after in-
fection, clones were selected in 1.2 μg/ml 
puromycin. A nontargeting (NT) shRNA was 
used as control. AKR-2B knockdown of Imp8 
and Impβ was performed in a similar manner. 
As two distinct shRNAs were used (#77 and 
#78) and multiple clones selected, the desig-
nation A.NT.8 and A.77.11, for example, re-
fers to AKR-2B (A) clone 8 or 11 expressing 
NT or the #77 SNX9 shRNA, respectively. 
When the pooled result from multiple clones 
is assessed (Figures 1 and 2), the #78 shRNA 
is referred to as Alt (alternative)-shRNA to dif-
ferentiate the shRNAs.
shRNA sequences included NT: 
CGAAAGTAGGTACATCCCTTA; SNX9 77 
clones: CCTGACTTGGATTTGATAGAA; 
SNX9 78 clones: CCTACTGACTACGTGG-
AAATT; Imp8 89 clones: GCACATTGTTAG-
AGAGACAAT; Impβ pool 5: GCG C T-
GTTAGACATGAGCTAA.
SNX9 rescue constructs were generated 
using QuickChange II XL (Agilent Technolo-
gies, Santa Clara, CA) by mutating nucleo-
tides 1164, 1167, and 1170 from T, C, G to 
G, T, A, respectively, while phosphoinositide 
binding and homodimerization mutants 
were prepared essentially as described 
(Childress et al., 2006; Yarar et al., 2008). 
Transfections used Transit 2020 (Mirus Bio, 
Madison, WI) and 2.5 μg DNA. Primers are 
provided in Supplemental Table S1.
Growth/migration studies
Soft-agar assays were performed as previ-
ously described (Rahimi et al., 2009). Briefly, 
4 × 104 cells were seeded in a six-well plate in 
the presence or absence of 10 ng/ml TGFβ 
(R&D Systems, Minneapolis, MN). Following 
10-d growth at 37°C, the number of colonies 
>100 μm in diameter were counted using 
an Optronix Gelcount (Oxford Optronics, 
Milton, Abingdon, UK). For scratch assays, 
cultures in 10% FBS/DMEM were seeded 
into six-well plates (5 × 105 cells/well) and in-
cubated overnight at 37°C. Following mono-
layer disruption using a sterile 200 μl pipette 
tip, the medium was changed to 0.5% FBS/
DMEM, and cultures were incubated in the 
presence or absence of TGFβ for 24 h. 
Images (×100) were taken at 0 and 24 h.
Luciferase reporter assays
Cultures were transfected with 2 μg of the indicated luciferase con-
structs together with 0.5 μg CMV-β-galactosidase using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA). For the ARE transfec-
tions, 2 μg of FAST1 was also cotransfected. The cells were serum 
SNX9 plasmids. Clones were selected using 1.2 μg/ml puromycin. For 
SNX9 knockdown, shRNA was generated using the lentiviral system 
from Sigma’s MISSION library, purchased from the Mayo Clinic Jack-
sonville RNA Interference Technology Resource. Briefly, plasmid con-
structs were transfected into 293FT cells and packaged using 
FIGURE 8: SNX9 and Imp8 differentially regulate pSmad3 association with the nuclear 
membrane and pore. (A) AKR-2B cells stably expressing nontargeting shRNA (NT; A-NT.8) or 
shRNA to SNX9 (shSNX9; A-77.7), Imp8 (shImp8; A-89.4), or Impβ (shImpβ; nonclonal 
population) were either left untreated or stimulated for 30 min with TGFβ and immunostained as 
indicated. (B) Quantification of nuclear and cytoplasmic Smad2 and Smad3 from 2 experiments ± 
SD. * denotes significant difference in nuclear R-Smad from similarly treated NT cells. (C) Top, 
AKR-2B cells described in A were stimulated with TGFβ for 30 min. Nuclear membrane (M), 
crude nuclear pore (P), and nuclear-soluble (S) fractions were prepared, and pSmad2 and 
pSmad3 were assessed. Bottom panel, determination of fraction purity from NT control cells. 
(D) First, Smad3 phosphorylation results in the binding of pSmad3 with SNX9 independent of 
Smad4. As the binding interactions, stoichiometry, and/or overall composition of the complex 
are currently unknown, this is indicated by the absence of any direct association depicted 
between the components. Second, SNX9 mediates pSmad3/SNX9 binding with the nuclear 
membrane. Third, nuclear membrane–associated Imp8 targets pSmad3 and SNX9 to the nuclear 
pore. Fourth, SNX9 dissociates from the nuclear membrane, while pSmad3 undergoes Impβ-
nuclear translocation (fifth).
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precleared for 1 h with either protein A or G agarose beads 
(Millipore, Charlottesville, VA) and incubated overnight (O/N) at 4°C 
with the indicated antibody. For prevention of masking of desired 
proteins by the immunoglobulin light chain, immunoprecipitating 
antibodies were cross-linked (before incubation) with BS3 (Thermo 
Fisher Scientific, Rockford, IL) per the manufacturer’s instructions, 
using a 15-fold molar excess of cross-linker (final cross-linker con-
centration of 0.25 mM). Immune complexes were collected by addi-
tion of protein A or G agarose beads (50 μl) and incubation for 2 h 
at 4°C. Following three washes in kinase lysis buffer, coimmunopre-
cipitated proteins were eluted in 2× Laemmli buffer and analyzed by 
Western blotting. For the detection of pSmad3 following immuno-
precipitation, blots were probed with pSmad3-specific antibodies 
(Cell Signaling Technology, Danvers, MA) and incubated in protein 
A–horseradish peroxidase conjugate (GE Healthcare, Pittsburgh, 
PA) (1:500 dilution), before processing for chemiluminescence 
detection.
GST fusion proteins were purified using the BugBuster GST Bind 
Purification Kit following the manufacturer’s instructions (Novagen, 
EMD4 Biosciences, Darmstadt, Germany). For assessment of SNX9 
binding to GST constructs, Cos7 cells were transfected with Flag-
TβRII (3 μg) and HA-TβRI (1 μg) using Lipofectamine 2000 (Invitro-
gen). Following O/N incubation, cultures were treated for 30 min 
with TGFβ before addition of kinase lysis buffer and HA immunopre-
cipitation (O/N at 4°C). TβRI was purified per the manufacturer’s 
recommendation using Catch and Release version 2.0 (Upstate Bio-
technology, Lake Placid, NY) and incubated in 50 μl kinase buffer 
(50 mM Tris [pH 7.4], 10 mM MgCl2, 1 mM dithiothreitol [DTT]) con-
taining 5 μM ATP, 5 μCi of [γ-32P]ATP per μl, and 2 μg substrate (GST-
Smad2 or -Smad3). The kinase assay was allowed to proceed for 
10 min at 37°C before incubation with AKR-2B lysate for 1 h at room 
temperature. Following the addition of glutathione-agarose beads 
(1 h at 4°C, rocking) and three washes with lysis buffer, bound SNX9 
was assessed by immunoblotting. For assessment of GST-SNX9 
binding of endogenous pSmad3, 500 μg of cell lysate was incu-
bated with 10 μg of GST-SNX9 (O/N at 4°C). Pull down and Western 
blotting was as described above.
Isolation of nuclear and chromatin-bound fractions
Nuclear membranes were prepared from NE-PER Nuclear and Cyto-
plasmic Extraction–purified nuclei (Thermo Scientific, Rockford, IL), 
followed by membrane extraction using the Subcellular Protein 
Fractionation Kit for Cultured Cells (Thermo Fisher Scientific) with 
the addition of 50 μg/ml PMSF, 100 μM sodium vanadate, 0.1 TIU/
ml aprotinin, and 1 μg/ml leupeptin to the lysis buffers. Following 
removal of the cytoplasmic extract, the nuclear pellet was washed 
three times in PBS containing 50 μg/ml PMSF, 100 μM sodium vana-
date, 0.1 TIU/ml aprotinin, and 1 μg/ml leupeptin before nuclear 
lysis and Western blot analysis. An alternative nuclear membrane 
fraction and a crude nuclear pore complex were generated as de-
scribed by Aaronson and Blobel (1975).
Nuclear soluble and chromatin-bound fractions were prepared 
using the Subcellular Protein Fractionation Kit (Thermo Scientific). 
Cell samples normalized by number were incubated on ice for 
10 min with gentle mixing in supplied cytoplasmic extraction buffer 
(CEB). Following centrifugation at 500 × g for 5 min, the samples 
were suspended in ice-cold membrane extraction buffer (MEB; sup-
plied) before centrifugation (1000 × g, 2 min) and incubation 
(10 min) of the pellet with gentle mixing in supplied CEB. Nuclei 
were pelleted at 3000 × g (5 min), and a soluble nuclear fraction was 
obtained by 30-min incubation in nuclear extraction buffer (NEB; 
supplied). The chromatin-associated fraction was acquired by 
starved in 0.1% FBS/DMEM overnight and either left untreated or 
stimulated with TGFβ for 24 h. Normalized luciferase activity was 
determined as described (Anders and Leof, 1996; Rahimi and 
Leof, 2007; Ross and Hill, 2008).
Immunofluorescence microscopy
Cells (2 × 104) were plated onto coverslips in 10% FBS/DMEM and 
incubated overnight at 37°C. Cultures were placed in 0.5% FBS/
DMEM alone or containing TGFβ for 45 min, rinsed twice with cold 
phosphate-buffered saline (PBS), and fixed for 30 min in 4% formal-
dehyde at room temperature. Subsequent to 0.2% Triton X-100 per-
meabilization (3 min at room temperature) and washing (0.2% bo-
vine serum albumin [BSA] in PBS, wash buffer), cultures were blocked 
in wash buffer containing 10% donkey serum for 1 h at room tem-
perature before the addition of primary antibody to Smad2 or Smad3 
in 0.2% BSA/PBS, 10% normal donkey serum for 1 h at room tem-
perature. Antibody information is listed in Supplemental Table S2. 
The coverslips were rinsed three times in wash buffer before room 
temperature incubation (10 min) in 50 mM NH4Cl to quench back-
ground fluorescence. Following an additional wash buffer rinse, 
samples were placed in either anti-AF488 (green) or AF-594 (red) 
secondary antibody (Invitrogen) to detect R-Smads or TAT-SNX9, re-
spectively, for 1 h at room temperature. Coverslips were washed 
three times (10 min each) with wash buffer and once in PBS before 
addition of mounting media containing 4′,6-diamidino-2-phenylin-
dole (DAPI; Invitrogen). Fluorescence images were collected on an 
LSM510 confocal microscope using MetaMorph software for image 
analysis and quantitation (Molecular Devices, Sunnyvale, CA).
YFP-SNX9 was detected as described for Smad2/3 with the fol-
lowing minor modifications. Subsequent to plating 5 × 105 cells/well 
(six-well plate) and 12 h of incubation at 37°C, cells were transfected 
with YFP-SNX9 (1.5 μg/well) and cultured for an additional 12 h be-
fore trypsination and seeding (2 × 104 cells) onto glass coverslips. 
Following 12 h of growth in 10% FBS/DMEM, the medium was 
removed and replaced with 0.5% FBS/DMEM ± TGFβ (5 ng/ml) for 
45 min. Fixation, permeabilization, and visualization was as above.
Quantitative reverse transcription (RT)-PCR analysis
Following TGFβ stimulation, total RNA was isolated using Trizol re-
agent (Invitrogen), and 2 μg was reverse transcribed (SuperScript III 
Reverse Transcriptase system; Invitrogen, CA). Samples were di-
luted 1:5 with water and one-fiftieth was used as template for qPCR 
with platinum SYBR green qPCR superMix-UDG (Invitrogen). Prim-
ers are presented in Supplemental Table S1; sample induction was 
normalized to GAPDH.
Western blotting, co-IP, and GST pull down
Cells were lysed for 30 min on ice in RIPA buffer (50 mM Tris [pH 7.4], 
1% Triton X-100, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM 
EDTA [pH 8] and 10 mM NaF) containing 50 μg/ml phenylmethyl-
sulfonyl fluoride (PMSF), 100 μM sodium vanadate, and 1 μg/ml leu-
peptin. Insoluble materials were pelleted by centrifugation at 
16,060 × g for 10 min, and 20–80 μg of protein was separated by 
SDS–PAGE. Antibodies are provided in Supplemental Table S2. 
Protein markers for fractionation studies included Impβ (nuclear 
membrane marker), histone 2B (chromatin-associated marker), his-
tone deacetylase 1 (soluble nuclear marker), and epidermal growth 
factor receptor (plasma membrane marker).
For co-IP, cells were lysed in kinase lysis buffer (50 mM Tris 
[pH 7.4], 0.1% Triton X-100, 250 mM NaCl, 5 mM EDTA [pH 8] and 
50 mM NaF) containing 50 μg/ml PMSF, 100 μM sodium vanadate, 
and 1 μg/ml leupeptin on ice for 30 min. Protein (500–800 μg) was 
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Statistical analysis
All p values were obtained through Student’s t test (two-tailed) 
comparisons.
suspending the remaining pellet in NEB containing CaCl2 and 
micrococcal nuclease (5 min, 37°C) and collecting the supernatant 
following a 16,000 × g spin for 5 min.
Dynamin GTPase assay
SNX9 KD cells were seeded at 2 × 105 cells per six-well culture dish 
and incubated at 37°C for 12 h before transient transfection with 
2.5 μg of the indicated SNX9 escape construct. Following a 24-h 
incubation, cultures were lysed in RIPA buffer for 30 min on ice, and 
SNX9 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was 
added to 500 μg cell protein before O/N incubation at 4°C. Immune 
complexes were precipitated by addition of agarose G beads for 1 h 
at 4°C and washed three times with cold PBS, and bound proteins 
were eluted with 50 mM glycine (pH 2.7). Dynamin GTPase activity 
was performed as described by Leonard et al. (2005). Briefly, 4 μl of 
eluted protein was incubated in 192 μl of GTPase assay buffer 
(20 mM HEPES-KOH [pH 7.5], 150 mM KCl, 2 mM MgCl2, 1 mM 
DTT) to which 4 μl GTP stock solution (100 mM GTP, 20 mM HEPES 
[pH 7.4]) was added. Following 10 min at room temperature, 100 μl 
was transferred to a 96-well microtiter plate containing 5 μl 0.5 M 
EDTA (pH 8.0) to stop the reaction. An equal volume (100 μl) of 
Malachite Green stock solution (1 mM Malachite Green, 10 mM 
ammonium molybdate in 1 N HCl) was added to each well, and 
GTPase activity (i.e., Malachite Green detection of free phosphate) 
was measured by absorbance at 650 nm using a microplate reader.
Generation of TAT fusion proteins
TAT-HA-SNX9 and TAT-HA-Smad3 proteins were prepared in 
BL21(DE3)pLysS Escherichia coli (OD600 of 0.4) following addition of 
isopropyl β-d-thiogalactopyranoside to a final concentration of 
0.5 mM. After a 4-h TAT protein induction at 37°C, cells were har-
vested, washed, and suspended in 15 ml 50 mM sodium phosphate 
buffer (pH 7.4) containing 300 mM NaCl and 20 mM imidazole. The 
cell suspension was sonicated, and the lysate was cleared by 
12,000 × g centrifugation at 4°C for 20 min. The supernatant was 
then poured into a TALON Metal Affinity Resin column (Clontech, 
Mountain View, CA), washed with 50 mM sodium phosphate buffer 
containing 40 mM imidazole, and eluted with 150 mM imidazole.
TAT-Smad3 nuclear entry/retention assays
Purified TAT-Smad3 was labeled with 125I using the Bolton Hunter 
reaction. After the samples were split, 50 μg was incubated in kinase 
buffer containing 5 μM ATP, 20 μCi [γ-32P]ATP per microliter and ac-
tivated TβR1-HA (purified by Catch and Release, as described 
above in the Western blotting, Co-IP, and GST pull down section, 
from TβRI- and TβRII-transfected Cos7 cells) to generate 32P-TAT-
Smad3 phosphorylated in the COOH terminal SSXS domain (S423/
S425). AKR-2B cells were grown to confluence in 24-well plates and 
transduced with 0.8 μM TAT-Smad3 or TAT-pSmad3 for the indi-
cated times. Plates were washed twice with binding buffer (0.2M 
HEPES, 2.5% BSA in DMEM [pH7.4]) containing 75% horse serum 
and twice with PBS before normalization for cell number. A third of 
the normalized sample was used for determination of total intracel-
lular TAT protein by cell lysis (0.2 M NaOH, 40 mg/ml salmon sperm 
DNA), while the remaining sample underwent nuclear fractionation 
and protein extraction as per NE-PER nuclear extraction recommen-
dations (Pierce, Rockford, IL). Nuclear counts were normalized to 
total cell counts (i.e., to account for the time delay in TAT-protein 
transduction; Supplemental Figure S2A), and maximal counts in NT 
cells were defined as 100%. Raw and normalized 125I and 32P TAT-
Smad3 cell transduction counts are provided in Supplemental 
Figure S2.
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